RNTX (Aileron Therapeutics) Multiplikator Forward P/S

Lambang korporat lan logo Rein Therapeutics Inc (RNTX)

The forward P/S of Rein Therapeutics Inc (RNTX) reflects revenue valuation dynamics, where the mark indicates the current trend level. Rein Therapeutics Inc develops targeted drugs based on the activation of cell death, protecting revenues with patents. The technology aims to eliminate resistant tumors for oncologists. Meanwhile, the asset value depends on the success of early tests and restructuring, ignoring general macroeconomic indicators.

Rein Therapeutics - Multiplikator Forward P/S RNTX (periode 04.07.2022 - 17.11.2026)

Ringkesan rincian data analitis Rein Therapeutics Inc (RNTX)

Analisis fundamental perusahaan:RNTX (Rein Therapeutics, Inc.)
Produk asli Aileron Therapeutics

Rein Therapeutics Inc (RNTX) is optimizing costs by outsourcing the development of oncology drugs to a network of external laboratories to scale its business. An analysis of the company's forward P/S ratio allows for a comparison of current market value against expected sales volume, determining the extent to which investor expectations regarding future revenues are overheated. This indicator helps balance aggressive revenue growth with financial stability, revealing a fair fundamental valuation of the asset.

Pesaing wigati

Rasio rega marang prakiraan pendapatan Vertex VRTX|ALNY (Alnylam Inc.) - Rega mangsa ngarep marang pendapatan|Insmed Incorporated - Multiplikator Forward P/S|Rega forward marang dodolan UTHR (United Therapeutics)|BMRN: Multiplikator Forward P/S|BridgeBio Pharma (BBIO) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan bgm.ltd|COGT: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan xerispharma.com (XERS)|Multiplikator forward rega marang pendapatan Keros Therapeutics KROS|Multiplikator Forward P/S ARCT (arcturusrx.com)|Multiplikator Forward P/S Eton Pharmaceuticals, Inc. ETON|KMDA - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan FULC|ABEO: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Mereo BioPharma Group PLC (MREO)|Multiplikator forward rega marang pendapatan PLX|Pliant Therapeutics (PLRX) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Applied Therapeutics (APLT)|Rasio rega marang pendapatan sing dikarepake GELS|Aytu BioPharma, Inc. - Multiplikator forward rega marang pendapatan|Chemomab Therapeutics (CMMB) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|SRx Health - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Polyrizon Limited PLRZ|AEZS: Multiplikator Forward P/S|CYTH: Rasio rega marang pendapatan sing dikarepake|Multiplikator forward rega marang pendapatan INZY|RPHM: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan CSCI (COSCIENS Biopharma)